Terry Blaschke, MD
Chief Science Officer
As Chief Science Officer, Terry Blaschke leads our scientific research operations. His vast involvement in clinical trials, with the FDA and with the pharmaceutical industry, has led to his interest in improving medication adherence and the efficiency of drug development using modeling and simulation.
Terry has over 180 original publications and 65 reviews and chapters and is Professor of Medicine and of Molecular Pharmacology (Emeritus) at Stanford University, Adjunct Professor in the Department of Bioengineering and Therapeutic Sciences at UCSF and Adjunct Professor of Medicine at Indiana University. From 2012 through 2015 he was a Senior Program Officer/Senior Advisor at the Bill and Melinda Gates Foundation.
Dr. Blaschke received his MD from Columbia University and his residency training at UCLA. Following fellowship training in Clinical Pharmacology at UCSF he joined the Stanford faculty in 1974. He is past president of the American Society for Clinical Pharmacology and Therapeutics, recipient of the Oscar B. Hunter award from ASCPT and the 2014 Award in Excellence in Clinical Pharmacology from the PhRMA Foundation. He was a member of the AIDS Clinical Trials Group at its inception, and served as chair of the Pharmacology Committee and on the Executive Committee. His research has focused on HIV infection, emphasizing the modeling of exposure-response relationships and adherence, especially in resource-limited settings.
Elizabeth Whalley Buono
Legal, Regulatory, and Policy
Liz Whalley Buono leads our legal, regulatory, and policy functions; providing advisory services to our clients on such matters. Liz has extensive experience in medication adherence and is one of the foremost experts in the legal and regulatory issues and opportunities involved in addressing medication non-adherence in various regions around the world. Liz received her BSN from Boston College School of Nursing and earned her MBA in Executive Management from St. John’s University. After extensive careers in clinical nursing and big pharma, she obtained a JD in Health Law and Economics from George Mason University School of Law. She practiced Food & Drug, Fraud & Abuse, Insurance and Privacy law at Wiley, Rein LLP in DC. In 2003, Liz joined Altria Client Services, managing the legal and health ethics considerations associated with clinical research and new product development activities undertaken in pursuit of tobacco harm reduction.
Liz joined MWV Healthcare in 2009 as Vice President of Global Quality, Regulatory and External Affairs. Most recently, Liz has founded and led a consultancy exploring novel health innovation opportunities including: Virginia’s first Pay for Success Social Impact Financing project and predictive algorithms for opioid overdose. Additionally, Liz has assisted in the development of new Virginia health care models funded through a $2.6 million federal SIM grant to the Virginia Center for Health Innovation.
Engineering and Technologies
Douglas Dobbs leads engineering and technology functions at The Arcady Group and for our clients. From product design, to product development, to supplier engagement, to technical leadership, Doug provides unsurpassed technical leadership to our innovation and product development activities.
Doug is a degreed mechanical engineer with extensive advanced training in all facets of consumer packaging. He has over 30 years of comprehensive experience in organizing and management of engineering and technical service functions in the research, design, development and commercialization of new products and manufacturing technologies.
Doug is an inventor/designer with dozens of patented dispensing packaging devices developed for low cost, mass production global manufacturing. He has worked for international corporations including MWV, Saint-Gobain, and Calmar in managing stage gate driven design-development-commercialization organizations with extensive experience in international project management.
Stacy Buchanan leads our communication efforts, particularly related to advocacy and global access. She leverages her deep understanding of medication adherence and human behavior to help The Arcady Group facilitate adoption of patient-centered adherence interventions for DS & MDR-TB.
Stacy draws on her more than 14 years of experience in pharmaceutical and communications-related roles, including 7 years working with Bruce at MWV to drive development and uptake of the industry’s largest portfolio of child resistant, adherence packages. While at MWV, Stacy supported pharmacies and manufacturers to introduce and scale adherence interventions. She advised on communications to multiple stakeholders throughout the supply chain in order to facilitate adoption of adherence packaging programs and ultimately influence patient medication-taking behaviors.
Her passions include wellness and disease prevention, helping patients overcome barriers to positive health outcomes, and person-centered care. Combined with her keen abilities to distill complexity and develop differentiated strategies, Stacy is well positioned to support The Arcady Group’s mission.
Stacy holds a B.S. in Marketing Management from Virginia Tech and an M.B.A. from Virginia Commonwealth University.